Blockade of the Serotonin and Norepinephrine Uptake Processes by Duloxetine: in Vitro and in Vivo Studies in the Rat Brain
Overview
Authors
Affiliations
In in vitro uptake experiments, duloxetine inhibited [3H]5-hydroxytryptamine (5-HT) and [3H]norepinephrine (NE) uptake in hippocampus slices of control rats with IC50 values of 28 and 46 nM, respectively. The uptake of both[3H]5-HT and [3H]NE was equipotently inhibited in hippocampus slices prepared from rats treated for 2 days with different doses of duloxetine (5, 10, 15 and 20 mg/kg/day s.c.). In in vivo electrophysiological experiments in the hippocampus, the effects of duloxetine on the suppression of CA3 pyramidal neuronal firing activity by microiontophoretically applied 5-HT and NE were examined with two modes of administration. Five successive i.v. injections (2 mg/kg each) significantly and dose-dependently prolonged the recovery time of the firing activity of hippocampus CA3 pyramidal neurons from the 5-HT applications. A 2-day treatment (10, 15 and 20 mg/kg/day s.c.) also increased the recovery time in a dose-dependent manner. Whereas the recovery time from NE applications was unaffected by low doses of duloxetine (2 mg/kg i.v.; 10 mg/kg/day for 2 days), it was prolonged significantly by higher doses (8 and 1 0 mg/kg iv.; 20 mg/kg/day for 2 days). Acute i.v. injections of duloxetine suppressed the spontaneous firing activity of dorsal raphe 5-HT and locus ceruleus NE neurons with ED50 values of 99 and 475 microgram/kg, respectively. Taken together, the present results confirmed that duloxetine is a dual 5-HT/NE uptake inhibitor. Furthermore, the results obtained in in vivo experiments indicate that duloxetine has a preferential inhibitory effect on the 5-HT transporter.
Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders.
Grinchii D, Dremencov E Int J Mol Sci. 2020; 21(24).
PMID: 33333774 PMC: 7765178. DOI: 10.3390/ijms21249532.
In vivo electrophysiological recordings of the effects of antidepressant drugs.
Fitzgerald P, Watson B Exp Brain Res. 2019; 237(7):1593-1614.
PMID: 31079238 PMC: 6584243. DOI: 10.1007/s00221-019-05556-5.
Duloxetine: a review of its use in the management of major depressive disorder in older adults.
Dhillon S Drugs Aging. 2012; 30(1):59-79.
PMID: 23239363 DOI: 10.1007/s40266-012-0040-1.
Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathy.
Wright A, Luedtke K, VanDenBerg C J Pain Res. 2011; 4:1-10.
PMID: 21386950 PMC: 3048581. DOI: 10.2147/JPR.S12866.
Lobo E, Heathman M, Kuan H, Reddy S, OBrien L, Gonzales C Clin Pharmacokinet. 2010; 49(5):311-21.
PMID: 20384393 DOI: 10.2165/11319330-000000000-00000.